News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 1308
- Sources here
- 21
- Companies here
- 23
Active search
1308 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Genasys Ex-Puerto Rico Quarter Shows How Dire Its Situation Is (NASDAQ:GNSS)
Genasys Inc. (GNSS) is rated a Hold due to its core business being deeply unprofitable outside of the Puerto Rico project. While recent profitability stemmed from this project, liquidity issues have paused it, revealing weak fundamentals. The company faces a strained balance sheet, costly …
Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership Changes - What's Changed
Zenas BioPharma reported widening losses in Q2 2026, with revenue dropping significantly year-over-year and net loss reaching US$111,460,000. These financial results were accompanied by leadership changes, including the CFO transitioning to a Strategic Advisor role and a new board appointment. The company's investment narrative …
Shenandoah Telecommunications Co (SH9) Q1 2024 Earnings Report - Results, Call & Slides
Shenandoah Telecommunications Co (SH9) reported its Q1 2024 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -€0.07 against a consensus of -€0.02 and actual revenue of €60.15M compared to an expected €62.12M, representing a 3.40% year-over-year decrease in …
Denali Therapeutics CEO Ryan J. Watts Donates 32,220 Shares to Donor Advised Fund
Denali Therapeutics Inc. CEO, Ryan J. Watts, donated 32,220 shares of common stock to a donor-advised fund on August 12, 2026, as disclosed in an SEC Form 4 filing. This charitable gift, valued at $0, was reported on August 14, 2026. Following the donation, …
Will Ciena's Rising Backlog Improve Revenue Visibility Into 2027?
Ciena Corporation is experiencing strong demand and a growing backlog, which is expected to provide increased revenue visibility into fiscal 2027. The company's backlog surged to $7.7 billion in Q2 fiscal 2026, with a significant portion anticipated to convert into revenue within the next …
Sharemaestro market context Price below Trend Line 52 weeks +324.3% · Next-week setup negative 31.7%Compañía de Minas Buenaventura y su nueva prioridad en pleno rally de metales
Compañía de Minas Buenaventura is shifting its focus to exploration over acquisitions due to record high metal prices, increasing its exploration budget by 30%. The company plans to maintain its CAPEX between US$385 million and US$415 million but will accelerate prospection and reevaluate mature …
Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim
Guggenheim reaffirmed its "buy" rating for Zenas BioPharma (ZBIO) with a $55 price target, despite the company reporting weaker-than-expected quarterly results, including an EPS loss of $1.77 and revenue of $1 million. Analyst sentiment for ZBIO remains generally positive with a "Moderate Buy" consensus …
Renasant Corp. (RNST) Q4 2025 Earnings Report - Results, Call & Slides
Renasant Corp. (RNST) released its Q4 2025 earnings, reporting an actual EPS of $0.83, surpassing the consensus of $0.78, and actual revenue of $394.53 million, significantly beating the expected $275.85 million. This represents a substantial year-over-year revenue growth of 52.78%. The company's earnings call …
Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush
Wedbush reiterated its "outperform" rating on Zenas BioPharma (NASDAQ:ZBIO) with a $45 price target, indicating a potential 54.11% upside. Despite this positive analyst sentiment, the company reported a significant miss on its quarterly earnings and revenue estimates. Other analysts have also adjusted their ratings, …
RTW Investments discloses 9.99% Tenax Therapeutics (TENX) position with 2.87M shares
RTW Investments and Roderick Wong, M.D. have reported a beneficial ownership of 9.99% in Tenax Therapeutics, Inc., amounting to 2,866,654 shares. This stake includes shares issuable upon the exercise of warrants, subject to a 9.99% beneficial ownership limitation. The filing, a SCHEDULE 13G/A, details …
Tema ETFs LLC Sells 48,552 Shares of Fastenal Company $FAST
Tema ETFs LLC significantly reduced its stake in Fastenal Company (NASDAQ:FAST) by 68.2% in the second quarter, selling 48,552 shares and retaining 22,629 shares valued at $1.09 million. Despite mixed analyst ratings, Fastenal reported strong quarterly revenue of $2.39 billion, a 14.7% year-over-year increase, …
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript
Denali Therapeutics reported Q2 2026 earnings, highlighting its transition to a commercial-stage company following the successful launch of AVLAYAH, a new therapy for Hunter syndrome. The company achieved $3.6 million in net product revenue in its first full commercial quarter and provided Q3 guidance …
Genasys Inc (GNSS) (Q3 2026) Earnings Call Highlights: Record Ba
Genasys Inc. Q3 2026 Earnings Call Summary - Moby Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Revenue decline …
ZenaTech, Inc. Expands ZenaWorx Drone-Based Construction Monitoring Software to Include Digital Terrain Modeling
ZenaTech, Inc. has expanded its ZenaWorx drone-based construction monitoring software to include digital terrain modeling (DTM) capabilities. This enhancement, offered through its Drone as a Service division, allows for precise measurement of cut-and-fill volumes, grading accuracy, and drainage during the earthworks phase of large …
ZenaTech Expands ZenaWorx Software with Digital Terrain Modeling, Signs First AI Data Center Customer
ZenaTech, Inc. has expanded its ZenaWorx construction monitoring software to include digital terrain modeling (DTM) capabilities, a move designed to enhance precision in large-scale construction projects like AI data centers. The company also announced its first paying customer in the AI data center construction …
Cadrenal Therapeutics Q2 Results: Net Loss Narrows To $3.3 Million
Cadrenal Therapeutics (NASDAQ: CVKD) reported a Q2 2026 net loss of $3.3 million, an improvement from $3.7 million in the prior year, primarily due to reduced R&D expenses. The company ended the quarter with $2.4 million in cash, which increased to $4.2 million in …
Genasys (NASDAQ:GNSS) Posts Earnings Results, Misses Estimates By $0.08 EPS
Genasys (NASDAQ:GNSS) reported its earnings, missing consensus estimates with an EPS of ($0.10) against an expected ($0.02), and revenue of $7.29 million against $15.47 million. Despite the miss, management reaffirmed its fiscal 2026 outlook for record revenue and profitability, citing a $69 million backlog, …
Genasys signals fiscal 2026 record year outlook as it expects to complete initial $9M CROWS delivery within the year
Earnings Call Insights: Genasys Inc. (GNSS) Q3 2026 MANAGEMENT VIEW * “Revenue for the fiscal third quarter was $7.3 million compared to $9.9 million in the prior year period,” and CEO Richard Danforth said the decline was driven by “2 timing-related factors,” including “the …
Renasant Corporation declares $0.24 quarterly dividend By Investing.com
Renasant Corporation announced a quarterly cash dividend of $0.24 per share, payable on September 30, 2026, to shareholders of record as of September 16, 2026. The company, which is the parent of Renasant Bank, manages approximately $27.0 billion in assets and operates 279 offices …
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock
Denali Therapeutics (NASDAQ:DNLI) insider Alexander Schuth sold 2,857 shares of the company's stock for approximately $71,625, reducing his position by 1% while still holding over 281,000 shares. Despite the company missing analysts' EPS estimates with a quarterly loss of $0.68 per share, revenue exceeded …
Genasys Inc earnings missed by $0.12, revenue fell short of estimates
Genasys Inc (NASDAQ: GNSS) reported third-quarter earnings per share (EPS) of $-0.100, missing analyst estimates by $0.12, and revenue of $7.3M, significantly below the consensus of $19.2M. The company's stock has seen a -4.470% decline in the last three months but is up 4.270% …